Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952530 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
A Phase 3 study of Hypertension, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 487
- Enrollment target
- 20
- Study locations
NCT06952530: Recruiting Phase 3 study of Hypertension, sponsored by Eli Lilly and Company.
NCT06952530 is a Phase 3 study of Hypertension that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 487 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06952530, a Phase 3 study of Hypertension, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 487 participants
- Enrollment target
- 20
- Study locations
Study Summary
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Florida
- Excel Medical Clinical Trials - Boca Raton
- Care Access - Brandon - Brandon
- Northeast Research Institute - Downtown Office - Jacksonville
- Peace River Cardiovascular Center - Port Charlotte
California
- Valley Clinical Trials, Inc. - Covina
- Valley Clinical Trials, Inc. - Northridge
Maryland
- Sinai Hospital Of Baltimore - Baltimore
- Ascension Saint Agnes Heart Care - Baltimore
Nevada
- Excel Clinical Research, LLC - Las Vegas
- Palm Research Center Sunset - Las Vegas
Arizona
- Elite Clinical Studies, LLC - Phoenix
Connecticut
- Chase Medical Research, LLC - Waterbury
Hawaii
- East-West Medical Research Institute - Honolulu
Massachusetts
- Lucida Clinical Trials - New Bedford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
What NCT06952530 shows while recruiting
NCT06952530 is an interventional study that assigns participants to a tested intervention. The registered 487 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06952530 names 20 study sites across 14 states, led by Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06952530 about?
NCT06952530 is a clinical study titled "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2". GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
What is the current status of trial NCT06952530?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 487 participants. The study started on 2025-04-30. Estimated completion is 2027-09.
What conditions does trial NCT06952530 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06952530?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06952530?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952530 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06952530's enrollment target sits among peer trials
487 125th of 470 higher than 345 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05154669 · 488 participants · Phase 3
Integrating Financial Coaching and Smoking Cessation Coaching
- NCT06532877 · 488 participants · NA
Telephone Support in Advanced Gastrointestinal Cancer
- NCT06602479 · 488 participants · Phase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
- NCT06794983 · 488 participants · NA
Calls and Coordination for Transitions of Care at Re-entry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI